The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2021 | Mortality in cancer patients with COVID-19: a systematic review
Elisa Agostinetto, MD, Istituto Clinico Humanitas, Rozzano, Milan, Italy, discusses the findings of a systematic review and meta-analysis conducted to assess for risk of mortality in adult patients with cancer and SARS-CoV-2 infection. The pooled analysis assessed more than 35,000 patients across 144 studies. The analysis showed a high probability of mortality, with a 25% case-fatality rate. When specific tumor types were assessed, lung cancer patients showed an even higher risk of mortality. The evaluation highlights the need for aggressive preventive measures against COVID-19 in cancer patients. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
